regorafenib
Bayer chalked up another approval for blockbuster-in-waiting Stivarga after Japan gave a green light for the drug's use in gastrointestinal stromal tumour (GIST).
This is the second approval for Stivarga (regorafenib) in Japan, having been cleared for the treatment of advanced or recurrent colorectal cancer in March. The product has already been approved for both indications in the US and is under review for the colorectal cancer indication in Europe
